Natera, Inc. logo

Natera, Inc.

NTRA

NASDAQHealthcareMedical - Diagnostics & Research

最新数据

US$331.62

+US$7.19 · +2.21%

8月21日 15:55 ET

NTRA公司概览

盘中时间采用ET。市场数据可能有所延迟。

GoAI 研究快照

简明呈现最新可用的模型信息。

2026年7月10日

GoAI评分

Hold

Wait — insufficient conviction to act

估值

65

Undervalued

动量

69

Gaining

情绪

47

Mixed

风险韧性

57

Elevated Risk

完整 GoAI 研究

继续查看更深入的依据、催化因素和风险。

查看完整研究

人工智能生成的上下文仅供参考,并非投资建议。

公司概况

公司网站

Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.

行业
Medical - Diagnostics & Research
部门
Healthcare
总部
US
首席执行官
Steven Leonard Chapman
上市以来
2015年7月1日
雇员
6,138

市场位置

成交量
121.51万
0.82× 平均值
平均成交量
147.97万
日均成交量
市值
475.52亿 USD
贝塔
1.51
市场参考 1

财报历史与展望

最新财年每股收益
-1.52
2025财年
最新财年收入
23.06亿 USD
2025财年 · 同比+35.90%

年度每股收益趋势

已公布业绩及可用的市场共识预期。

已公布市场共识预期
年度每股收益趋势-1.12-2.74-4.36-5.9821财年22财年23财年24财年25财年

年度营收趋势

已公布业绩及可用的市场共识预期。

已公布市场共识预期
年度营收趋势24.74亿18.02亿11.3亿4.57亿21财年22财年23财年24财年25财年

NTRA同业公司

继续GoAI的研究

在 GoAI 中研究NTRA

research.disclaimer